Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors

Author： Muller Alexander J   Malachowski William P   Prendergast George C  

Publisher： Informa Healthcare

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.9, Iss.4, 2005-08, pp. : 831-849

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Indoleamine 2,3-Dioxygenase in Immune Suppression and Cancer

By  

Current Cancer Drug Targets, Vol. 7, Iss. 1, 2007-02 ,pp. : 31-40

Bentham Science Publishers

Access to resources Recommend Favorite

Indoleamine 2,3-dioxygenase, Tregs and Cancer

By  

Current Medicinal Chemistry, Vol. 18, Iss. 15, 2011-05 ,pp. : 2240-2246

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 9, Iss. 2, 2009-06 ,pp. : 151-177

Bentham Science Publishers

Access to resources Recommend Favorite

How Does Indoleamine 2,3-Dioxygenase Contribute to HIV-Mediated Immune Dysregulation

By  

Current Drug Metabolism, Vol. 8, Iss. 3, 2007-04 ,pp. : 217-223

Bentham Science Publishers

Access to resources Recommend Favorite

Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008 – 2012)

By Dolušić Eduard   Frédérick Raphaël  

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 10, 2013-10 ,pp. : 1367-1381

Informa Healthcare

Access to resources Recommend Favorite